Mature T-cell lymphomas (MTCLs) have an extremely poor prognosis and are much less frequent than immature T-cell leukemias. This suggests that malignant outgrowth of mature T lymphocytes is well controlled. Indeed, in a previous study we found that mature T cells are resistant to transformation with known T-cell oncogenes. Here, however, we observed that T-cell receptor (TCR) mono-/oligoclonal mature T cells from TCR transgenic (tg) mice (OT-I, P14) expressing the oncogenes NPM/ALK or DTrkA readily developed MTCLs in T-cell-deficient recipients. Analysis of cell surface markers largely ruled out that TCR tg lymphomas were derived from T-cell precursors. Furthermore, cotransplanted non-modified TCR polyclonal T cells suppressed malignant outgrowth of oncogene expressing TCR tg T lymphocytes. A dominant role of an anti-leukemic immune response or Tregs in the control of MTCLs seems unlikely as naïve T cells derived from oncogene expressing stem cells, which should be tolerant to leukemic antigens, as well as purified CD4 and CD8 were resistant to transformation. However, our results are in line with a model in which homeostatic mechanisms that stabilize the diversity of the normal T-cell repertoire, for example, clonal competition, also control the outgrowth of potentially malignant T-cell clones. This study introduces a new innate mechanism of lymphoma control.
INTRODUCTION
Mature T-cell lymphomas (MTCLs) are infrequent, but their incidence is rising and distinct nodal, leukemic, cutaneous and extra-nodal forms have just recently been defined as coherent clinico-pathological and in part molecular entities. The prognosis is generally dismal and the development of novel therapeutic options is difficult as little is known about the pathogenesis and the mechanisms that control MTCL development. 1 In MTCLs, just like in any other tumor (B-cell lymphoma, even solid tumors), clonal homeostasis is obviously disturbed. Although, mechanisms that stabilize the T-cell repertoire have been described, it is completely unclear why homeostatic control fails and malignant clones can expand and gain prevalence in MTCLs. The currently widely accepted clonal competition model for normal T-cell homeostasis postulates that T-cell clones compete for interaction with antigen presenting cells (APCs). This interaction is assumed to be essential for T-cell survival and proliferation. 2 According to this model, clonal abundances are regulated on a per-clone basis, and the affinity of a particular T-cell receptor (TCR) to major histocompatibility complex/self-peptide (MHC/SP) complexes presented on APCs crucially affects the steady-state abundance of the corresponding T-cell clone. [3] [4] [5] The heterogeneity of the T-cell repertoire is thus preserved through the heterogeneity of the MHC/SP complexes (T-cell niches) presented in the host. 2, 6 Here, we experimentally tested the hypothesis that clonal competition not only stabilizes the normal T-cell repertoire, but also suppresses malignant clonal outgrowth. This hypothesis was derived from our previous finding that (proto-)oncogenes known to cause T-cell malignancies in transgenic mice and/or associated with T-cell lymphoma in man (TCL1, LMO2, DTrkA) do not cause transformation, when selectively expressed in mature murine TCR polyclonal T-cell populations. 7 
MATERIALS AND METHODS

Ethics statement
The experiments were performed in compliance with the local animal experimentation guidelines. Animal experiments were approved by the regional council (Regierungspräsidium) Darmstadt, Hessen, Germany.
Mice
Six-to 8-week-old C57BL/6J.Ly5.1 (CD45.1 þ ), TCR tg OT-I (CD45.2 þ ) and Rag-1-deficient (CD45.2 þ ) mice were obtained from Charles River laboratories (Sulzfeld, Germany) and Jackson laboratory (Bar Harbor, ME, USA). P14 TCR tg mice were kindly provided by the laboratory of Professor Dr Ulrich Kalinke (Institute for Experimental Infection Research, TWINCORE, Centre for Experimental and Clinical Infection Research, Hannover, Germany). The TCR tg mice were leaky with 5-10% T cells that did not express the transgenic TCR in OT-1 and P14 mice. Animals were bred and maintained under specific pathogen-free (SPF)-like conditions in the animal facilities of the Georg-Speyer-Haus. Cages were individually ventilated. Symptomatic/leukemic or healthy animals (donors) were killed after anesthesia by cervical dislocation and examined for pathological abnormalities, including histology, morphology, white blood cell (WBC) counts and flow cytometry.
synthetized cDNA from the company GENEART (Regensburg, Germany) and cloned into the gammaretroviral vector MP91-eGFP 5-prime of an internal ribosome entry site from the encephalomyocarditis virus and the gene for the enhanced green fluorescence protein (EGFP).
Retroviral vector production
Vector supernatants were produced in DMEM (Bio Whittaker, Rockville, MD, USA) supplemented with 10% fetal calf serum (PAN BIOTECH GmbH, Aidenbach, Germany), 2% L-glutamine (Bio Whittaker), 1% of Penicillin/ Streptomycin (Pen/Strep) (PAN BIOTECH GmbH). Ecotropic supernatant was produced in a split genome approach by calcium-phosphatemediated transient transfection of HEK 293T human embryonic kidney producer cells. After 24, 48 and 60 h supernatant was collected, filtered (45 mm) and stored at 4 1C. All supernatants were pooled and titrated on the embryonic murine fibroblast SC-1 cell line.
Retroviral transduction and transplantation of Lin
À HSCs/HPCs or mature T cells Bone marrow cells were flushed from tibias and femurs of C57BL/6J.Ly5.1 donor mice. Enrichment of Lin À cells was carried out with the Mouse Lineage Cell Depletion Kit (Miltenyi Biotec, Bergisch-Gladbach, Germany) following the manufacturer's protocol. Lin À Cells were cultivated in Stem Span SFEM medium (STEMCELL Technologies, Vancouver, BC, Canada), supplemented with 10 ng/ml murine SCF, 20 ng/ml murine TPO, 20 ng/ml murine IGF-2 and 10 ng/ml human FGF-1 (Tebu-bio, Offenbach, Germany). Twenty-four-well non-tissue culture plates (BD, San Diego, CA, USA) were coated with 50 mg/ml retronectin (Takara Bio Inc., Tokyo, Japan), according to the manufacturer's protocol and preloaded with retroviral supernatants (loading of retronectin coated plates: 1 ml of vector supernatant per well; 1000 g, 4 1C, 30 min). Lin À cells were cultured on particle-covered plates and transduction was performed only once to ensure single-cell copies in the transduced cells. Five days after isolation and transduction, 5 Â 10 5 bone marrow cells were injected intravenously into Rag-1-deficient recipients. Before transplantation (4-6 h) mice were sublethally irradiated with 5 Gy using a BIOBEAM 2000 Cs-137 chloride gamma irradiator (Eckert & Ziegler, Berlin, Germany).
Expansion and transduction of stimulated T cells was as previously described. 7 Five days after isolation and after two rounds of transduction, 5 Â 10 6 transduced mature T cells were injected intravenously into Rag-1-deficient recipients. For competition experiments 5 Â 10 6 transduced TCR tg OT-I or P14 T cells were mixed with 5 Â 10 6 stimulated, untransduced wild-type (WT) C57BL/6 (Ly5.1) T cells before transplantation.
Serial transplantation of different DTrkA-expressing cell populations Six weeks after the transplantation HSC/HPC-DTrkA recipients were killed. In all, 1 Â 10 6 total bone marrow, 1 Â 10 6 total thymocytes and 5 Â 10 6 CD3 negatively selected, naïve mature T cells from the lymph nodes (purity 490% CD3 þ ) were serially transplanted from primary recipients into secondary Rag-1 À / À animals. Negative selection of T cells was performed using the Dynal Mouse T-Cell Negative Isolation Kit (Invitrogen, Carlsbad, CA, USA).
Flow cytometry analysis and WBC counts of leukemia/lymphoma samples Immediately before killing and necropsy, blood was obtained from symptomatic animals and a hemogram was prepared to determine the WBC count using a Scil vet animal blood counter (Scil animal care company GmbH, Viernheim, Germany).
Flow cytometry analyses were carried out on blood and single-cell suspensions of thymus, spleen, lymph nodes and bone marrow. The following anti-mouse monoclonal antibodies (MoAbs) were used for staining: rat anti-mouse MoAbs (Invitrogen); phycoerythrin (PE)-conjugated CD8a (CT-CD8a), PE Cy5.5 (PE-Cy5. 
Histopathological analysis
Obviously sick mice, presenting scrubby fur, a crooked body appearance and a complete loss of activity and/or with a high WBC were killed for necropsy and examined for pathological abnormalities. After securing single-cell suspensions of infiltrated organs for FACS analysis, lymph nodes, spleen, thymus, liver, kidney, lung, heart, brain and bone marrow were fixed in 10% Zinc-Formal-Fixx (Thermo Shandon, Pittsburgh, PA, USA). Sections were prepared and stained with hematoxilin and eosin. For histological examination a light microscope (Eclipse E1000m Nikon, Tokyo, Japan) with Â 4, Â 20, Â 40 and Â 200 lenses with a digital camera (DXM 1200, Nikon) was used.
Retroviral insertion site analysis and statistical analyses
Methods for retroviral integration site (RIS) analysis and -associated statistics can be found in the Supplement.
RESULTS
Resistance of naïve polyclonal as well as purified CD8 and CD4 T cells to transformation by overexpression of DTrkA In a previous study, we found that upon transduction with gammaretroviral vectors expressing a T-cell oncogene mature T cells, in contrast to hematopoietic stem/progenitor cells (HSCs/HPCs), do not develop leukemia/lymphoma. 7 However, in this previous study we investigated the transformability of memory but not of naïve T cells. The reason was that the T cells had to be activated to become susceptible to gammaretroviral vectors and thereby acquired a memory phenotype.
To study whether naïve T cells are also resistant to transformation, HSCs/HPCs from three C57BL/6 Ly5.1 mice were transduced with the gammaretroviral vector SF91-DTrkA expressing an oncogenic, constitutively active form of TrkA 8 or with MP91-eGFP as a control vector (Supplementary Figure S1 ) and then transplanted into five sublethally irradiated Rag-1 À / À Ly5.2 mice (Figure 1a ). In our previous study, 7 DTrkA was the most potent oncogene, with which we had shown resistance of memory T cells to development of MTCLs. The Ly5 marker allowed differentiation of donor (Ly5.1) and recipient cells (Ly5.2). Six weeks after transplantation, before DTrkA-associated lymphoma developed, bone marrow, thymocytes and CD3 þ T cells, purified by negative selection (purity 490% CD3 þ ) from the lymph nodes, were harvested from each mouse. At this time point over 90% T cells have a naïve phenotype (CD44low, data not shown). The average DTrkA expression in these populations was 12%, 32% and 25%, respectively (Supplementary Figure S2a) . Each population was serially transplanted into Rag-1 À / À recipients ( Figure 1a ). All recipients were repopulated with DTrkA-expressing cells at a level between 14 and 25% in the periphery (data not shown). HSC/ HPC and thymocyte transplanted mice of the DTrkA-group succumbed to lymphoma within 1-5 months (Figure 1b) . The malignancies were all EGFP positive and displayed an immature T-cell phenotype, as previously described. 7 However, the mice transplanted with DTrkA-expressing naïve T cells remained healthy with normal leukocyte levels and no macroscopic signs of lymphoma throughout a follow-up of 9 months (Figure1b) with stable expression levels of DTrkA (Supplementary Figure S2b) . Thus, in our experimental setup naïve peripheral T cells were also resistant to transformation by overexpression of DTrkA.
In addition, the results argue against the hypothesis that a specific anti-leukemic immune response significantly contributes to the control of T-cell lymphoma in this setting with the investigated oncogene. Naïve T cells derived from transplanted DTrkA expressing HSCs/HPCs should be tolerant to DTrkA or potential T-cell lymphoma-associated antigens and therefore should be unable to exert a specific anti-leukemic immune response. Furthermore, the fact that serially transplanted naïve T cells as well as the transplanted memory T cells in our previous study 7 stably expressed the oncogene over months also argues against a lymphoma-specific immune response in these settings.
To further test the anti-leukemic immune response hypothesis, we transplanted purified CD4 or CD8 cells, either expressing EGFP or DTrkA (n ¼ 5 per group). During the follow-up of 300 days, none of the animals developed malignancies, although stable transgene expression levels were maintained (data not shown). The development of a potent de novo anti-leukemic immune response within the CD4 or CD8 population alone appears unlikely, thus again arguing against a significant role of an anti-leukemic immune response in lymphoma control. In addition, the outcome of this experiment shows that regulatory T cells are not required for the suppression of malignant outgrowth, as oncogene transduced polyclonal CD8 T cells alone did not develop any malignancy. Finally, as observed in our previous study, 7 the transgenes were expressed stably throughout the observation period in the polyclonal T-cell population without the development of MTCLs, which is not expected if an immune response specifically eliminated potentially malignant T-cell clones.
TCR diversity suppresses development of MTCLs To address the clonal competition hypothesis, we used T cells from TCR transgenic (tg) OT-I 10 and P14 (ref. 11) donor mice. No interclonal competition is expected in these TCR tg T-cell populations and each TCR tg T cell is subjected to the same niche regulation. The clonal competition hypothesis predicts that control of clonal outgrowth due to niche dependency will fail in this situation, and premalignant cells can indeed expand and gain prevalence.
For these studies, we switched to the T-cell-specific oncogene ALK expressed as the NPM/ALK fusion protein. ALK was chosen because preliminary experiments had shown that ALK-induced malignancies develop more rapidly than DTrkA-induced lymphomas. Furthermore, ALK is well proven to be associated with anaplastic large cell lymphoma (ALCL) in humans. 9, 12, 13 Mature T cells were collected from the spleen and the lymph nodes of healthy C57BL/6 Ly 5.1 (WT) mice, as well as from TCR tg OT-I mice. Cells were transduced ex vivo with a gammaretroviral vector coexpressing NPM/ALK and EGFP (MP91-NPM/ALK) or with a control vector expressing EGFP only (MP91-eGFP, Supplementary Figure S1 ). The transduction efficacies were 18% and 8% for NPM/ALK expressing WT T cells and OT-I TCR tg T cells, respectively (Supplementary Figure S3a) . Gene-modified cells were transplanted into T-cell-deficient Rag-1 À / À recipients (5 Â 10 6 per mouse, Figure 2a ). As predicted by the clonal control hypothesis, all mice transplanted with OT-I TCR tg T cells (n ¼ 10) that expressed NPM/ALK succumbed to lymphoma within 30-80 days post transplantation (Figure 2b ). Only two of the mice transplanted with NPM/ALK expressing WT T cells (n ¼ 6) developed lymphoma, however, after a considerably longer latency period (161, 229 days). All animals had enlarged lymph nodes and splenomegaly. The histology resembled human mature peripheral nodal T-cell lymphoma (Figure 4 ). Mice transplanted with cells expressing the control vector (n ¼ 10) remained healthy throughout the whole observation period (data not shown).
The clonal competition hypothesis also predicts that polyclonal T cells will suppress the development of lymphoma from Figure 2 ). This observation further corroborates the hypothesis that polyclonal T cells suppress the development of MTCLs. In addition, this result demonstrates that T cells are not per se resistant to transformation. Furthermore, it shows that even if a T cell expressing a tg TCR was more susceptible to transformation, it is still accessible to the control within a polyclonal T-cell population. Taken together, the findings are in line with the hypothesis that oncogene expressing TCR tg T-cell populations develop lymphoma because they lack external homeostatic control exerted by polyclonal T cells. Transformability of TCR oligoclonal T-cell populations-a more general phenomenon To determine whether the observed control of malignant outgrowth is a more general phenomenon, we tested whether other oncogenes can transform TCR tg T cells and whether other TCR tg T cells can be transformed. OT-I as well as P14 TCR tg T cells were transduced with a DTrkA-expressing vector or with MP91-eGFP and transplanted into Rag-1 À / À mice. Additionally, animals were transplanted with P14 TCR tg T cells transduced with the NPM/ALK oncogene (n ¼ 6). Again, a group of Rag-1 À / À mice was transplanted with 5 Â 10 6 DTrkA-expressing OT-I T cells alone (n ¼ 20) or together with 5 Â 10 6 WT TCR polyclonal competitor T cells (n ¼ 6, Figure 3a) . Transduction efficacies of the transplants are shown in Supplementary Figure S3b .
As expected, none of the control mice transplanted with OT-I or P14 transgenic T cells expressing only EGFP developed lymphoma. In contrast, all animals transplanted with DTrkA-and NPM/ALKexpressing TCR tg T cells (OT-I or P14) developed lymphoma, however, for DTrkA with a longer latency than for NPM/ALK (Figures 3b and c) . The mice showed a macroscopic and histological phenotype typical of a peripheral nodal lymphoma (Figure 4 ). For the OT-I/DTrkA plus competitor group, only one of the six animals developed lymphoma with a delay of more than 100 days relative to the group transplanted with OT-I TCR tg T cells expressing DTrkA. Thus, the enhanced susceptibility of TCR oligoclonal T-cell populations to develop T-cell lymphomas is neither specific for NPM/ALK nor for OT-I TCR tg T cells, but a more general phenomenon.
Phenotype analyses of induced tumors
The phenotypes of all lymphomas were analyzed in detail (Table 1  and Supplementary Table S1 ). As frequently observed for lymphomas in humans, marker expression was not stringent and often markers from different lymphocyte lineages were coexpressed, while several typical T-lineage markers were missing (CD3, TCR). Nevertheless, NPM/ALK-induced lymphomas could be classified as T-cell lymphomas as all expressed at least one pan-Tcell marker. For the P14-NPM/ALK group, all tumors expressed at least two pan-T-cell markers and the coreceptor CD4 (Table 1) . Interestingly, 8 of 10 OT-I-NPM/ALK and 6 out of 6 P14-NPM/ALK tumors expressed inducible costimulator (ICOS), a marker highly specific for T lymphocytes (Supplementary Table S1 ). Out of the 21 lymphomas that developed from DTrkA-expressing lymphocytes, 16 expressed at least one pan-T-cell marker. Four DTrkA-induced lymphomas expressed CD19, a B-cell marker. All three DTrkAtransformed P14 lymphomas analyzed expressed ICOS as a T-cellspecific antigen, one of the three coexpressed CD19. None of the CD19-expressing lymphomas analyzed were found to have a recombined B-cell receptor, which excluded a mature B-cell origin (data not shown). The expression of ICOS on the majority of the lymphomas suggests that these lymphomas may have developed from follicular T helper cells. 14 We could initiate cell cultures from spleen and lymph nodederived lymphoma cells of diseased NPM/ALK animals. Furthermore, established cell lines were injected intravenously into secondary recipients, which developed histologically and immunophenotypically identical malignancies as presented in the primary tumors (data not shown).
To further exclude immature T-cell transformation in our experimental setup, we transduced TCR tg OT-I T cells with the proto-oncogene LMO2 and transplanted these cells into Rag-1 À / À animals. As LMO2 transforms immature T cells 15 and is characterized by a long latency (9-12 months), we observed transplanted animals for over 360 days. None of the animals developed leukemia/lymphoma, although the proto-oncogene was stably expressed in the recipients (data not shown).
Induced MTCLs were negative for immature T-cell markers and NPM/ALK-induced tumors resembled an 'ALCL-like' phenotype As we were using TCR tg donor animals (OT-I and P14) on a Rag-1 þ / þ background, we checked the rearrangement status of the intrinsic TCR-beta-chain on the genomic level in the tumors. Unfortunately, we were not able to detect any rearranged gene segments for the intrinsic TCR chain (data not shown), most likely because of the expression of the tg TCR during maturation in the thymus. In all analyzed tumors we were able to detect the transgene for the OT-I receptor on the genomic level. A further genomic analysis of the alpha chain seems rather difficult, as to our knowledge, there is currently no reliable protocol available. Thus, we could not rely on the prevalent method of TCR rearrangement analysis to determine the differentiation status of the lymphomas. We therefore analyzed immature T-cell markers, that is, CD117, TdT, pre-TCR alpha chain, in the T-cell transplants and lymphomas. We were not able to detect immature T-cell markers in our transplants (WT or TCR tg), in which 495% of cells expressed a TCR (data not shown). In addition, no cells expressing the immature T-cell markers analyzed were detected in our tumor samples (Supplementary Table S1 ).
However, in accordance with an 'ALCL-like' phenotype of NPM/ ALK-induced tumors in transgenic mice, 12 CD30 was highly expressed and the signal transducer and activator of transcription 3 (Stat-3p) was phosphorylated in all NPM/ALK tumors analyzed ( Figure 5 ).
Retroviral integration analysis of induced MTCLs
In this study, we used gammaretroviral vectors with a strong LTR enhancer. To determine the potential contribution of insertional mutagenesis to lymphoma development, we analyzed the distribution of retroviral integration sites (RISs). Despite the fact, that there is a substantial proportion of tumors with a lost transgene expression, we detected RISs in all analyzed tumors. Downregulation of the transgene could possibly reflect that in these cases tumor sustenance became independent from oncogene addiction after accumulation of secondary mutations during tumorigenesis. A total of 131 RISs were identified in 31 tumors (a detailed list of all RIS surrounding genes, in a ±250 kb window can be found in Supplementary Table S2 , with a preference for gene-dense regions (Po0.001) and the ± 10 kb windows around transcription start sites (Po0.001 Supplementary Figure S4 ), as previously described for gammaretroviral vectors. 16, 17 Furthermore, a twofold overrepresentation (Po0.001) of RTCGD genes 18 was observed among the genes in the ± 250 kb window of the RISs (Supplementary Table S3 ). We found two RISs in the vicinity of the RTCGD gene Dnalc4 with a distance of only 1536 bp in two independent lymphomas fulfilling the classical definition of a common insertion site of first order. 19 The probability to observe a RIS pair within such a window among 131 uniformly distributed RISs would be 0.01. Additionally, six RIS pairs had a distance of o320 kb to each other, among them two pairs with a RTCGD gene in their close proximity (LMO2, PIM1) (Supplementary Figure S5) . The common insertion site near LMO2 is of special interest as insertional mutagenesis of a gammaretroviral vector leading to activation of LMO2 was previously found to lead to T-cell leukemia in children treated for X-linked severe combined immunodeficiency with a stem cell gene therapy regimen. 20, 21 Gene ontology (GO) analysis of RIS-flanking genes revealed several significantly overrepresented GO classes (Mus musculus genome as reference set). Although the analyzed dataset is small, we could observe differences in GO classes between malignant clones from DTrkA-and NPM/ALK-induced tumors (Supplementary Figures S6a-c) . Taken together, these findings suggest that in addition to the chosen oncogenes, most likely insertional mutagenesis contributed to the transformation of TCR tg T cells in this study.
DISCUSSION
The by far lower incidence of MTCLs relative to B-cell lymphomas is thought to be due to additional steps of error prone B-cell receptor gene rearrangements and affinity maturation during B-cell differentiation. Our study suggests that, in addition, the stronger clonal cross-control of T cells relative to B cells could explain why B-cell homeostasis is more readily perturbed than T-cell homeostasis. Indeed, the presented in vivo data are reminiscent of this 'clonal competition model' of T-cell homeostasis. When applied to the maximal perturbation of T-cell homeostasis, the MTCLs, this model would predict that T-cell competition for stimulatory MHC/SP niches also controls the outgrowth of potentially malignant T-cell clones. In this study, several predictions of this hypothesis were tested and confirmed: (1) in contrast to polyclonal T cells, TCR tg T cells were highly susceptible to transformation with the oncogenes DTrkA and NPM/ALK; (2) addition of polyclonal T cells suppressed the malignant outgrowth of oncogene expressing TCR tg T cells; (3) purified TCR polyclonal CD4 and CD8 were resistant to transformation in vivo; (4) naïve polyclonal T cells were resistant to transformation by DTrkA, while thymocytes and HSCs/HPCs were readily transformed; (5) the induced MTCLs expressed several markers of mature T cells (CD2, CD4, CD5, CD25, ICOS) and the phenotype of NPM/ALK-induced MTCLs closely resembled human ALCL.
The currently best-available mouse models for MTCLs are based on the CD4-Cre inducible expression of T-cell oncogenes 12, 22 or inactivation of T-cell-specific tumor suppressors. 23 One major drawback of these models is that oncogene expression is initiated at the CD4 þ CD8 þ stage of T-cell development. As this is highly unlikely to be the target cell of transformation in mature T-cell neoplasms, we decided to directly modify mature T cells isolated from the secondary lymphoid organs spleen and lymph nodes. Indeed, the phenotype of the induced tumors was similar to that of human MTCLs. NPM/ALK-induced lymphomas resembled human ALCL much more closely than previous transplantation mouse models for NPM/ALK. 13, 24 As typical for ALCL, the expression of specific T-cell markers was lost (Table 1,  Supplementary Table S1 ), while other markers such as CD30, ICOS and phosphorylated Stat3 were highly expressed in the used transplantation model. In contrast, these markers are rarely found in transgenic models of NPM/ALK. The proposed model can easily be established and the results obtained are thus expected to be of potential interest for modeling human MTCLs.
We also observed a loss in T-cell marker expression in the MTCLs induced in this study (Table 1, Supplementary Table S1 ). Marker loss is a common feature in NPM/ALK-induced ALCL. 25, 26 Moreover, in a previous study, we also observed a downregulation of mature T-cell markers after immortalization of a mature T-cell clone. 27 To further exclude an immature T-cell contamination in our experimental setting, we transduced OT-I T cells with the immature T-cell proto-oncogene LMO2. Just like in our previous study, 7 LMO2 overexpression in mature T cells did not result in malignancy development. This is in line with the general opinion that the transforming capacity of an oncogene is highly dependent on the analyzed cell type.
Our experimental system is highly relevant for evaluating the safety of T cell-based gene therapies and clearly supports the assumption that therapeutic transfer of polyclonal T cells transduced with integrating vectors is generally safe. However, T cells transduced with a recombinant TCR can expand after reinfusion in the presence of the cognate antigen and thus finally dominate the T-cell repertoire. 28, 29 Subsequently, in such a 'TCR-oligoclonal situation' our data would predict that preleukemic clones are controlled less efficiently. Further studies need to be performed to test the safety of TCR-associated adoptive immunotherapy regimens, that is, the question of how much 'TCR-polyclonality' is required to suppress malignant outgrowth should be addressed.
Another possible explanation for suppression of MTCLs in our experimental setting could be that WT T cells outcompete transduced TCR tg T cells during engraftment. However, for DTrkA-transduced TCR tg T cells transplanted in combination or without WT T cells, levels of gene modification in the blood of recipient animals was initially very similar (data not shown).
Clearly, our performed experiments do not completely rule out an immune response in addition to other mechanisms, but to our knowledge a specific immune response cannot be mounted in the absence of T-cell help (CD8 purified T cells were also resistant to transformation). Subsequently, in our mouse model, a specific anti-leukemic immune response seems not to have a pivotal role in MTCLs control. Also a dominant role of NK cells is unlikely in our setting, as these are not present in the cotransplanted purified WT T cells but were present in the recipient Rag-1 À / À mice for the monoclonal, as well as for the polyclonal transplants.
In general, the efficacy of clonal cross-control of (pre-)malignant clones is expected to be dependent on the mode of action and the 'strength' of the oncogene involved. Here, individual predictions are difficult as little is known about the mechanisms involved in clonal cross-control in normal T-cell homeostasis. Further studies will be required that compare homing capacity, gene expression and signaling pathways ex vivo in monoclonal T cells expressing an oncogene in the presence and absence of cotransplanted WT T cells.
The clonal cross-control model is also in accordance with two recently published studies, in which MTCLs developed in TCR tg mice. Kelly et al. 30 reported the development of thymic T-cell lymphoblastic lymphomas in TCR tg mice, in which Stat5a or Stat5b is overexpressed within the lymphoid compartment. The rate of lymphoma induction was markedly enhanced by immunization or by the introduction of TCR transgenes. In a second study, Tsatsanis et al. 31 crossed the TCR transgene 2C, which recognizes class I MHC presented peptides, into the Tpl2 À / À genetic background. Parental mouse strain (Tlp2
and 2C transgenic mice) showed no signs of T-cell malignancy. Surprisingly, all TCR2Ctg/tg/Tpl2 À / À mice developed T-cell lymphomas with a latency of 4-6 months. The tumor cells were consistently TCR2C þ CD8 þ CD4 À suggesting that they were derived from chronically stimulated mature tg T cells.
The clonal competition model would explain several typical features of human T-cell lymphomas. T cells are long-lived and experience massive perturbations of the repertoire with clonal expansion and retraction during antigen encounters followed by long-term persistence of the evolved memory cell clones. Surprisingly, however, in this highly versatile system, the T-cell repertoire remains fairly stable up to an age of around 65 years and outgrowth of malignant T-cell clones is a rare event.
32 Mature T-cell malignancies are much less frequent than their immature counterparts. For instance, although HTLV-I transforms mature T cells readily in vitro, only a small fraction of infected patients develop leukemia after long-term persistence of the virus in mature T cells. 33 In addition, MTCLs mostly develop in tissues such as skin, lymph node or mucosa, and locally perturbed T-cell repertoires have been found to precede malignancy. 34 Autoimmune diseases and chronic infections involving chronic T-cell stimulations and dominance of specific T-cell clones are often associated with MTCLs. 35, 36 For example, patients with complicated celiac disease (refractory celiac disease), bearing a monoclonal T-cell infiltrate, are described to be especially prone to enteropathy-associated T-cell lymphoma. 37 Taken together, we propose a model in which inter-and intraclonal competition among T cells does not only stabilize the normal T-cell repertoire, but also suppresses malignant clonal outgrowth. This would be a completely new mechanism of natural resistance to a malignancy and could explain why MTCLs are so rare. Further studies on the molecular effector mechanisms of clonal cross-control may fuel the development of innovate treatment strategies that improve the dismal prognosis of MTCLs.
